Compared with both CAR T cell monotherapy alone and combination therapy, mice treated with anti-PD-1-secreting CAR T cells had a significantly higher ratio of CD8+ versus CD4+ T cells at the tumor site [133]. This evidence concerns the gene CD8A and neoplasm.